EUVIMEDEUVIMED entdecken
Crossref

Sex Differences in Presentation, Treatment, and Survival in Patients Receiving Palliative (Chemo)Radiotherapy for Non-Small Cell Lung Cancer

Carsten Nieder, Siv Gyda Aanes, Astrid Dalhaug, Ellinor Christin Haukland

Anticancer Research · 2024

DOI: 10.21873/anticanres.16812 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2024. Verfasst von Carsten Nieder und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway; carsten.nieder@nlsh.no. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: The aim of this study was to analyze sex differences in a real-world cohort of patients who received palliative thoracic radiotherapy or chemoradiotherapy for non-small cell lung cancer. PATIENTS AND METHODS: Retrospectively, baseline, treatment, toxicity, and survival data from a single institution were analyzed. The study included 181 patients (82 females, 99 males). RESULTS: Despite borderline significant differences in disease presentation (T and N stage), final assignment to stage II, III or IV was similar. The same was true for target volume size. Neither radiotherapy parameters nor systemic treatment approaches were significantly different. Toxicity profiles and survival were similar too. Less than 1 out of 3 patients experienced high-grade toxicity, largely esophagitis. Median survival was 8.1 (males) versus 7.8 months (females) and the corresponding 2-year survival rates were 16 and 15%, respectively (p=0.78). CONCLUSION: Relevant sex differences were not observed in this study of common radiotherapy regimes such as 10 fractions of 3 Gy or 15 fractions of 2.8 Gy, the latter often combined with carboplatin/vinorelbine chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansFemaleMaleRetrospective StudiesSex CharacteristicsAntineoplastic Combined Chemotherapy ProtocolsCarboplatinChemoradiotherapyNeoplasm Staging

Stichwörter der Autor:innen

Non-small cell lung canceroverall survivalprognosisradiotherapysexside effects

Substanzen

Carboplatin

Autor:innen und Institutionen

  • Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway; carsten.nieder@nlsh.no.
  • Department of Clinical Medicine, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway.
  • Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway.
  • SHARE - Center for Resilience in Healthcare, Faculty of Health Sciences, Department of Quality and Health Technology, University of Stavanger, Stavanger, Norway.

Zitieren

APA

Nieder, C., Aanes, S. G., Dalhaug, A., & Haukland, E. C. (2024). Sex Differences in Presentation, Treatment, and Survival in Patients Receiving Palliative (Chemo)Radiotherapy for Non-Small Cell Lung Cancer. Anticancer Research. https://doi.org/10.21873/anticanres.16812

Vancouver

Nieder C, Aanes SG, Dalhaug A, Haukland EC. Sex Differences in Presentation, Treatment, and Survival in Patients Receiving Palliative (Chemo)Radiotherapy for Non-Small Cell Lung Cancer. Anticancer Research. 2024. doi:10.21873/anticanres.16812

BibTeX
@article{Nieder2024,
  author = {Nieder, Carsten and Aanes, Siv Gyda and Dalhaug, Astrid and Haukland, Ellinor Christin},
  title = {Sex Differences in Presentation, Treatment, and Survival in Patients Receiving Palliative (Chemo)Radiotherapy for Non-Small Cell Lung Cancer},
  journal = {Anticancer Research},
  year = {2024},
  doi = {10.21873/anticanres.16812}
}
Kostenlos starten →